| abstract |
The present disclosure relates to somatic ErbB2 mutations in cancer and provides methods for identifying, diagnosing, and prognosing ErbB2 positive cancers. The present disclosure further provides methods of treating cancer involving certain patient subpopulations. The mutation is in the transmembrane or juxtamembrane domain of ErbB2. [Selection diagram] Figure 1 |